Drug upates 2012 in review and approvals

Nurse Practitioner

Volumn 38, Issue 2, 2013, Pages 24-42

  Belavic, Jennifer M ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Acne; Cushing syndrome; Diabetic macular edema; Erectile dysfunction; HIV; Obesity; Overactive bladder; Respiratory distress syndrome

Indexed keywords

EID: 84876215805     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/01.NPR.0000425824.44694.e8     Document Type: Article

References (6)

1. American Academy of Dermatology. Acne: who gets and causes. www.aed.org/sink-conditions/dermatology-ato-z/acne/who-gets-causes/ acne-who-gets-and-causes.
2. Anon. FDA approves Fabior Foam. www.drugs.com/newdrugs/stiefel-receives- us-fda-approval-fabior-foam-0-1-3214.html.
3. Shalita AR, Berson DS, Thiboutot DM, et al. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. Clin Ther. 2004;26(11):1865-1873.
4. Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol. 2000;43:S31-S35.
5. Fabior (tazarotene) Foam, 0.1% Prescribing Information. Stiefel Laboratories, Inc. 2012. www.stiefel.com/content/dam/stiefel/globals/documents/ pdf/US-Fabior.pdf.
6. Kakita L. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris. J Am Acad Dermatol. 2000;43(2 pt 3):S51-S54.